Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
Urological Science, 2019 Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the paradigm of anticancer therapy in many cancer types, including advanced urothelial carcinoma (UC).
Jhe-Cyuan Guo +2 more
doaj +2 more sources
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
Chinese Medical Journal, 2017 Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj +3 more sources
Indian Journal of Dermatology, 2021 Background: Extramammary Paget's disease (EMPD) is a rare skin cancer and sometimes has fatal prognosis. For progressive cases, therapeutic options are limited.
Hiroyuki Goto +2 more
doaj +3 more sources
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism [PDF]
Endocrine Connections, 2018 Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar +3 more
doaj +5 more sources
Status of programmed death-ligand 1 expression in sarcomas [PDF]
Journal of Translational Medicine, 2018 Background Sarcomas are challenging to study because of their rarity and histomorphological complexity. PD1 and PD-L1 inhibitors showed a promising anti-tumor effect in solid tumors, where a relationship between PD-L1 expression and the objective ...
Hyung Kyu Park +5 more
doaj +3 more sources
Pembrolizumab in programmed death ligand 1-positive endometrial cancer [PDF]
Journal of Clinical Oncology, 2017 In the article by Ott et al, the aim of the study, KEYNOTE-028 (NCT02054806), was to evaluate the activity and safety profile of pembrolizumab in patients with heavily pretreated advanced endometrial cancer (EC), a subgroup with a poor prognosis. This article deserves some consideration to give the study proper meaning.
BENEDETTI PANICI, Pierluigi +2 more
core +5 more sources
Melatonin, programmed death ligand-1, programmed death ligand-1, and cancer: imagine beyond the future? [PDF]
Rev Assoc Med Bras (1992)Soares Junior JM, Sengul I, Sengul D.
europepmc +4 more sources
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis [PDF]
International Journal of Molecular Sciences, 2021 Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes.
Ioannis A. Vathiotis +3 more
openaire +3 more sources
Immunohistochemical Expression of Programmed Death Ligand-1 and CD-8 in Glioblastoma [PDF]
QJM: An International Journal of Medicine, 2021 Background Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor in adults. It is characterized by its extremely poor prognosis despite the available treatment strategies. Immune evasion is described in Glioblastoma via the PD-L1/ PD-1 interaction.
Dina Mohamed El Samman +5 more
openaire +3 more sources
Programmed death-ligand 1 expression in rectal cancer [PDF]
European Surgery, 2016 Colorectal cancer (CRC) is the fourth most common cause of death worldwide. Approximately 30 % of all CRC occurs in the rectum. Improvements in survival rates were achieved thanks to multimodal therapy, combining surgery and chemoradiation. Nevertheless, the prognosis of patients suffering from rectal cancer (RC) remains poor.
Jomrich, G. +4 more
openaire +2 more sources